DHA supplementation and pregnancy outcomes
DHA supplementation and pregnancy outcomes
复制标题
DOI：
10.3945/ajcn.112.050021
复制
发表时间：
2013-04-01
影响因子：
7.1
通讯作者：
Shaddy, D. Jill
中科院分区：
文献类型：
--
作者：
Carlson, Susan E.;Colombo, John;Shaddy, D. Jill
背景：观察性研究将孕期n-3 （omega-3）长链多不饱和脂肪酸（LCPUFAs）的高摄入量与更长的妊娠期和出生尺寸联系起来。使用不同n-3 LCPUFA来源和量的随机补充试验的结果是混合的。目的：验证600 mg/d的n-3 LCPUFA二十二碳六烯酸（DHA）可以增加产妇和新生儿DHA状态、妊娠期、出生体重和体长的假设。评估了安全性。设计：该III期，双盲，随机对照试验于2006年1月至2011年10月进行。妇女（n = 350）服用胶囊（安慰剂，DHA）
Background: Observational studies associate higher intakes of n-3 (omega-3) long-chain polyunsaturated fatty acids (LCPUFAs) during pregnancy with higher gestation duration and birth size. The results of randomized supplementation trials using various n-3 LCPUFA sources and amounts are mixed.Objective: We tested the hypothesis that 600 mg/d of the n-3 LCPUFA docosahexaenoic acid (DHA) can increase maternal and newborn DHA status, gestation duration, birth weight, and length. Safety was assessed.Design: This phase III, double-blind, randomized controlled trial was conducted between January 2006 and October 2011. Women (n = 350) consumed capsules (placebo, DHA) from